Nanfang Hospital, Southern Medical University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

182

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

8 drugs in development

Approved2

Phase 33

Phase 25

Phase 12

Preclinical2

By Therapeutic Area

top 4

Oncology

969%

Dermatology

18%

Psychiatry

18%

Gastroenterology

18%

R&D Momentum

71/100

Pipeline Velocity

39/100

Trial Completion Rate

93/100

Pipeline Concentration

50/100

Pipeline Freshness

39/100

Strategic Signals

↗Active in Dermatology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 3, 2026

Terminated

RemImazolam Besylate for ICU-sedation in Patients With Mechanical Ventilation After Oral and Maxillofacial Surgery: Multicenter, Randomized, Non-inferiority Clinical Study

Jul 2, 2026

Completed

The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism

Earlier

Jun 24, 2026TrialDoxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patient Receiving Radiotherapy for Nasopharyngeal Carcinoma: A Multicenter, Randomized, Controlled, Double-Blind Clinical Trial

Apr 1, 2026TrialEffect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study

Mar 1, 2026TrialEfficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis

Jan 1, 2026TrialProspective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B

Dec 25, 2025TrialQL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

Dec 1, 2025TrialSorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Showing 15 of 18 programs

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)